INSIGHTS & POINT OF VIEW Sage Thoughts

View More
250x250 - 1
At the Crossroads of Innovation and Policy, People Suffer
LEARN MORE
Brain Works
LEARN MORE
Conversations: "A Clinical Perspective on Sage Science – from Bench to Patient"
LEARN MORE

News The latest from Sage

press releases

Sage Therapeutics to Present at Upcoming May Investor Conferences

events

2023 RBC Capital Markets Global Healthcare Conference

sage thoughts

At Sage, we believe we see possibilities where others do not and are working to find potential ways to treat people with brain health disorders. Sage Thoughts provides insights and points of view about brain health.

See All News

PATIENTS & CARE PARTNERS Putting patients and their families first

We are rethinking care and how it is delivered to help patients and families impacted by brain health disorders.

See our resources for patients
Asian woman on a solid blue background wearing a gray t-shirt and a ponytail looking off into the distance

HEALTHCARE PROVIDERS It’s an exciting time in neuroscience

At Sage, our goal is to originate meaningfully differentiated drug candidates. We aim to discover new pathways to brain health by making medicines that matter so patients can get better, sooner.

 

LEARN MORE ABOUT OUR APPROACH

CLINICAL TRIALS A distinct approach to neuroscience drug development

Sage is committed to developing new medicines to treat life-altering brain health disorders.
LEARN MORE ABOUT OUR ONGOING CLINICAL TRIALS

PIPELINE Advancing a leading brain health portfolio

We seek to make a positive impact on the unmet treatment needs of patients by advancing product candidates from a robust development pipeline of potential brain health disorder treatments.
Compound
Partners
Indications
Preclinical
Phase 1
Phase 2
Phase 3
Registration
Marketed
Depression Franchise
ZULRESSO
(brexanolone) CIV injection
Postpartum Depression
100
Zuranolone
(SAGE-217)
Major Depressive Disorder
79
Postpartum Depression
79
Treatment Resistant
50
Generalized Anxiety Disorder
50
Bipolar Depression
50
NEUROLOGY FRANCHISE
SAGE-324
Essential Tremor
40
Epileptiform Disorders
29
Parkinson's Disease
29
SAGE-689
Acute GABA Hypofunction
19
NEUROPSYCHIATRY FRANCHISE
SAGE-718
Huntington's Disease Cognitive Dysfunction
40
Parkinson's Disease Cognitive Dysfunction
40
Alzheimer's Disease Mild Cognitive Impairment and Mild Dementia
40
ADDITIONAL CLINICAL PROGRAMS
SAGE-319
GABA Hypofunction
19
SAGE-421
NMDA Hypofunction
11

Please refer to the U.S. Prescription Information for brexanolone

- - - indicates trials in the planning or evaluation stage

Safety and efficacy for investigational uses or compounds have not been established. There is no guarantee that the outcome of these studies will be positive or result in the approval by a Health Authority.

Learn More About Our Programs and Research

CAREERS Rethinking brain health disorders to make life better for patients and their families

Sage is a place where unconventional thinking to solve problems with new ideas is welcome - and where unconventional thinkers can imagine what's possible and do big.
EXPERIENCE OUR CULTURE
We have recently updated our Privacy Policy to include information regarding the cookies we collect. By continuing to use this website you agree to our Privacy Policy and Terms of Use .
ACCEPT